OTC Events

2020 Therapeutics Showcase

Thursday, March 5, 2020
1pm – 5pm
The Blackwell at The Ohio State University
2110 Tuttle Park Place, Columbus, OH 43210

Learn about impactful therapeutic innovations as well as new pharmaceutical startup companies generated from Abigail Wexner Research Institute at Nationwide Children’s Hospital.  Join us for six talks highlighting novel therapeutics interventions from Nationwide Children’s researchers.

Register Now

Presentations:

Genetically Engineered NK Cells for Cancer Immunotherapy

A new approach to genetically modifying hard-to-engineer human Natural Killer cells improves their antitumor activity.

Presenter:
Meisam Naeimi Kararoudi, DVM, PhD Post-Doctoral Fellow, Cellular Therapy and Cancer Immunology Program, Nationwide Children’s Hospital

Anti-LYST Therapy: A Novel Immunomodulator

LYST is a protein coded by the lysosomal trafficking regulator gene. Through a series of investigations, modulation of LYST has been shown to alter the immune response dramatically affecting a variety of biological processes including wound healing, scarring, fibrosis, recovery from ischemic injury, and tissue regeneration. In this presentation, the work developing an initial clinical target and an anti-LYST antibody decorated biodegradable barrier for preventing post-surgical adhesions will be showcased.

Presenter:
Christopher Breuer, MD Director, Center of Regenerative Medicine & Founder of Lyst Therapeutics, Nationwide Children’s Hospital Professor of Pediatric Surgery, The Ohio State University

AAV-Based Targeting of X-Inactivation as a Potential Therapeutic Strategy for X-Linked Loss of Function Disorders

A platform approach for AAV gene therapy targeting loss-of function mutations in X-linked genes will be presented.

Presenter:
Kathrin Meyer, PhD Principal Investigator, Center for Gene Therapy, Nationwide Children’s Hospital Associate Professor, The Ohio State University

Respiratory Viruses and Asthma

Respiratory viral infections are known to drive development of asthma and wheezing. The Grayson Lab has a tractable mouse model that tests potential therapeutics, including INV-102, to prevent the development of post-viral asthma/wheezing.

Presenter:
Mitchell Grayson, MD Chief, Division of Allergy and Immunology, Nationwide Children’s Hospital Professor of Pediatrics, The Ohio State University
Robert Shalwitz, MD CEO, Invirsa

Viral Delivery of Exon Skipping Construct to Treat Duchenne Muscular Dystrophy

Viral delivery of exon skipping construct (AAV.U7) overcomes the limitations of antisense oligonucleotides that also mediate exon skipping, as AAV.U7 efficiently targets all muscles and has a long lasting effect.

Presenter:
Nicolas Wein, PhD Principal Investigator, Center for Gene Therapy, Nationwide Children’s Hospital Assistant Professor, The Ohio State University

Gene Therapies for GNE Myopathy

A new gene therapy technology has been designed not only to stop disease progression but to reverse disease for patients with GNE myopathy.

Presenter:
Paul T. Martin, PhD Principal Investigator, Center for Gene Therapy, Nationwide Children’s Hospital Professor of Physiology and Cell Biology, The Ohio State University

Panel Discussion:

"From Bench to Bedside to Business: Advancing Federally Funded Initiatives into the Marketplace"

  • Timothy Cripe, MD, PhD, Division Chief, Hematology/Oncology/BMT, Nationwide Children’s Hospital, Professor of Pediatrics, The Ohio State University
  • Dean Lee, MD, PhD, Director, Cellular Therapy and Cancer Immunology Program, Nationwide Children’s Hospital, Professor of Pediatrics, The Ohio State University
  • Joseph Trebley, PhD, Founder and CEO, Scioto Biosciences, Inc.
  • Moderator: John Barnard, MD, Chief of Pediatrics at Nationwide Children’s Hospital, President of the Abigail Wexner Research Institute at Nationwide Children’s Hospital

Register Now